Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of 11.27% is 221% above its 5-year average of -9.34%, near the high end of its 5-year range (-31.05%–11.27%).
380.35% above its 12-month average of -4.02%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): 10.08%.
RETURN ON ASSETS (ROA)
11.27%
RETURN ON ASSETS (ROA) AVG TTM
-4.02%
RETURN ON ASSETS (ROA) AVG 3Y
-13.89%
RETURN ON ASSETS (ROA) AVG 5Y
-9.34%
RETURN ON ASSETS (ROA) AVG 10Y
-23.12%
RETURN ON ASSETS (ROA) AVG 15Y
-31.78%
RETURN ON ASSETS (ROA) AVG 20Y
-70.69%
CURRENT VS TTM AVG
+380.35%
CURRENT VS 3Y AVG
+181.12%
CURRENT VS 5Y AVG
+220.66%
CURRENT VS 10Y AVG
+148.74%
CURRENT VS 15Y AVG
+135.46%
CURRENT VS 20Y AVG
+115.94%
SECTOR MEDIAN · HEALTHCARE
-28.05%
median of 546 covered companies
CURRENT VS SECTOR MEDIAN
+140.19%
vs the sector median at left
BioLife Solutions, Inc.
Market Cap
$1.89B
Return on Assets (ROA)
11.27%
TTM Avg
-4.02%
3Y Avg
-13.89%
5Y Avg
-9.34%
Market Cap
$1.86B
Return on Assets (ROA)
1.78%
TTM Avg
2.10%
3Y Avg
3.84%
5Y Avg
3.40%
Market Cap
$1.86B
Return on Assets (ROA)
-37.11%
TTM Avg
4.34%
3Y Avg
-11.90%
5Y Avg
4.27%
Market Cap
$1.93B
Return on Assets (ROA)
-45.02%
TTM Avg
-50.76%
3Y Avg
-46.27%
5Y Avg
-37.50%
Market Cap
$1.83B
Return on Assets (ROA)
10.25%
TTM Avg
8.68%
3Y Avg
8.17%
5Y Avg
8.38%
Market Cap
$1.96B
Return on Assets (ROA)
-11.05%
TTM Avg
-19.34%
3Y Avg
-25.88%
5Y Avg
-26.23%
Market Cap
$1.80B
Return on Assets (ROA)
-46.66%
TTM Avg
-46.30%
3Y Avg
-40.19%
5Y Avg
-33.55%
Market Cap
$1.99B
Return on Assets (ROA)
-44.98%
TTM Avg
-76.52%
3Y Avg
-94.59%
5Y Avg
-76.85%
Market Cap
$2.00B
Return on Assets (ROA)
-11.00%
TTM Avg
-5.98%
3Y Avg
-9.46%
5Y Avg
-10.43%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BioLife Solutions, Inc. (BLFS) | $1.89B | 11.27% | -4.02% | -13.89% | -9.34% |
| Astrana Health, Inc. (ASTH)vs › | $1.86B | 1.78% | 2.10% | 3.84% | 3.40% |
| Agios Pharmaceuticals, Inc. (AGIO)vs › | $1.86B | -37.11% | 4.34% | -11.90% | 4.27% |
| Absci Corporation (ABSI)vs › | $1.93B | -45.02% | -50.76% | -46.27% | -37.50% |
| LeMaitre Vascular, Inc. (LMAT)vs › | $1.83B | 10.25% | 8.68% | 8.17% | 8.38% |
| Establishment Labs Holdings Inc. (ESTA)vs › | $1.96B | -11.05% | -19.34% | -25.88% | -26.23% |
| Intellia Therapeutics, Inc. (NTLA)vs › | $1.80B | -46.66% | -46.30% | -40.19% | -33.55% |
| Immunome, Inc. (IMNM)vs › | $1.99B | -44.98% | -76.52% | -94.59% | -76.85% |
| AxoGen, Inc. (AXGN)vs › | $2.00B | -11.00% | -5.98% | -9.46% | -10.43% |
| Generate Biomedicines, Inc. (GENB)vs › | $1.76B | -61.53% | -47.53% | -47.53% | -47.53% |
ROA
11.3%
ROE
12.0%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -2.99% |
| 2024-12-31 | -5.05% |
| 2023-12-31 | -16.48% |
| 2022-12-31 | -31.05% |
| 2021-12-31 | -1.61% |
| 2020-12-31 | 1.14% |
| 2019-12-31 | -1.78% |
| 2018-12-31 | -55.00% |
| 2017-12-31 | -20.71% |
| 2016-12-31 | -86.73% |
| 2015-12-31 | -34.07% |
| 2015-01-31 | -20.02% |
| 2013-12-31 | -32.33% |
| 2012-12-31 | -52.36% |
| 2011-12-31 | -117.73% |
| 2010-12-31 | -151.53% |
| 2009-12-31 | -207.53% |
| 2008-12-31 | -237.06% |
| 2007-12-31 | -392.80% |
| 2006-12-31 | -202.35% |
| 2005-12-31 | -138.52% |
| 2004-12-31 | -89.19% |
| 2003-12-31 | -43.97% |
| 2002-12-31 | 68.78% |
| 2001-12-31 | -248.24% |
| 2000-12-31 | -69.49% |
| 1999-12-31 | -54.45% |
| 1998-12-31 | -46.50% |
| 1997-12-31 | -40.99% |
| 1996-12-31 | 0.00% |
